Epirus Biopharmaceuticals
Boston
About Epirus Biopharmaceuticals
EPIRUS is focusing on the central development of a broad pipeline of biosimilar monoclonal antibodies and therapeutic proteins, optimized for use within the SCALE™ disposable manufacturing system, and designed to be deployed in an "In Market, For Market" ™ manufacturing configuration.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Total funding: $127.3M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jan 2015)
- Ticker: nasdaq:EPRSQ
- Website: epirusbiopharma.com
- Phone: +1 6176073437
Industries & Categories
Biotechnology, Life Science, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/epirus-biopharmaceuticals-2666504 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.